ArticleCureus2026
Pharmacological Management and Longitudinal Cognitive, Psychiatric, and Behavioral Changes During Stem Cell Therapy in a Patient With Mesial Temporal Sclerosis: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polypharmacy is common in epilepsy, particularly in patients with psychiatric comorbidities requiring concomitant pharmacological treatment. Long-term treatment often increases the risk of adverse drug reactions and pharmacological interactions. Stem cell therapy has emerged as a topic of growing interest in neurology because of its immunomodulatory and neuromodulatory properties. We report the case of a 15-year-old female patient with mesial temporal sclerosis characterized by marked cognitive and psychiatric comorbidities requiring a complex five-drug pharmacological regimen. The patient underwent treatment with autologous stem cells harvested from the superficial abdominal fascia and was followed clinically for one year. During follow-up, the patient also continued to receive antiepileptic treatment, psychopharmacological management, psychotherapy, and multidisciplinary clinical care. Throughout follow-up, individualized pharmacological optimization was performed under close clinical monitoring. This case highlights the importance of individualized pharmacological management during longitudinal multidisciplinary care. The report describes the longitudinal clinical course and pharmacological optimization of a patient with mesial temporal sclerosis undergoing stem cell therapy within a broader multidisciplinary treatment framework.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.